Keywords: data, shows, patients, prefer, amgen, twice-yearly, inj
Data shows patients prefer Amgen's twice-yearly inj to Merck & Co's daily tab
Article | 22 September 2008
The USA's Amgen presented telling data from head-to-head trials comparing its candidate denosumab to Merck & Co's blockbuster Fosamax (alendronate) at ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
